15142-87-7 Usage
Uses
Used in Pharmaceutical Industry:
2H-spiro[isoquinoline-1,4'-piperidine]-3(4H)-one is utilized as a key intermediate in the synthesis of new drugs or bioactive molecules due to its distinctive spirocyclic structure. Its unique configuration allows for the exploration of its potential in developing medications with diverse therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2H-spiro[isoquinoline-1,4'-piperidine]-3(4H)-one serves as a valuable compound for studying its biological activities and potential interactions with biological targets. This research can lead to a better understanding of its pharmacological properties and its use in the design of effective therapeutic agents.
Used in Drug Discovery:
2H-spiro[isoquinoline-1,4'-piperidine]-3(4H)-one is employed in drug discovery processes as a starting point for the development of innovative pharmaceuticals. Its structural attributes make it an attractive scaffold for the creation of new chemical entities with potential therapeutic benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 15142-87-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,1,4 and 2 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 15142-87:
(7*1)+(6*5)+(5*1)+(4*4)+(3*2)+(2*8)+(1*7)=87
87 % 10 = 7
So 15142-87-7 is a valid CAS Registry Number.
15142-87-7Relevant articles and documents
SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN
-
, (2016/06/15)
The present invention relates to spiro-isoquinoline-1,4'-piperidine compounds having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
-
, (2009/10/21)
This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD l in mammals.Formula (I).
NPY antagonists: spiroisoquinolinone derivatives
-
, (2008/06/13)
A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula I. As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.
